1356446-78-0

Basic information

• Product Name: Fosinopril impurity D
• Synonyms: Fosinopril impurity D;(4R)-4-Cyclohexyl-1-[(R)-[(S)-1-hydroxy-2-Methylpropoxy](4-phenylbutyl)phosphinyl]acetyl-L-proline Propionate SodiuM Salt;(2S,4R)-4-Cyclohexyl-1-[[(R)-[(1S)-2-methyl-1-(1-oxopropoxy)propoxy](4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid
• CAS NO: 1356446-78-0
• Molecular Formula: C30H46NO7P
• Molecular Weight: 563.66
• Mol File: 1356446-78-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Fosinopril impurity D(CAS DataBase Reference)
• NIST Chemistry Reference: Fosinopril impurity D(1356446-78-0)
• EPA Substance Registry System: Fosinopril impurity D(1356446-78-0)

Safety Data

• Hazardous Substances Data: 1356446-78-0(Hazardous Substances Data)

Upstream product

• 128948-00-5 C₁₉H₂₉O₆P 
• 90657-55-9 trans-4-cyclohexyl-L-proline hydrochloride 
• 120851-71-0 (2S,4S)-1-Benzoyl-4-phenyl-pyrrolidine-2-carboxylic acid 
• 96314-26-0 trans-4-phenyl-L-proline 
• 103201-78-1 (2S,4S)-4-cyclohexylpyrrolidine-2-carboxylic acid 
• 31560-20-0 (2S,4R)-1-benzoyl-4-hydroxypyrrolidine-2-carboxylic acid methyl ester 

Relevant articles and documents

Preparation methods of antihypertensive Fosinopril sodium and key intermediate thereof

The invention relates to preparation methods of an antihypertensive Fosinopril sodium and a key intermediate thereof trans-4-phenyl-L-proline suitable for industrial production. Synthesis of the key intermediate trans-4-phenyl-L-proline has high chiral selectivity, and the method is simple and easy to operate.

COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING SALT SENSITIVITY OF BLOOD PRESSURE

To characterize the urinary exosome miRNome, microarrays were used to identify the miRNA spectrum present within urinary exosomes from ten individuals that were previously classified for their salt sensitivity status. The present application discloses distinct patterns of selected exosomal miRNA expression that were different between salt-sensitive (SS), salt-resistant (SR), and inverse salt-sensitive (ISS) individuals. These miRNAs can be useful as biomarkers either individually or as panels comprising multiple miRNAs. The present invention provides compositions and methods for identifying, diagnosing, monitoring, and treating subjects with salt sensitivity of blood pressure. The applications discloses panels of miRNAs useful for comparing profiles, and in some cases one or more of the miRNAs in a panel can be used. The miRNAs useful for distinguishing SS and SR or ISS and SR subjects. One or more of the 45 miRNAs can be used. Some of the miRNAs have not been previously reported to be circulating. See those miRNAs with asterisks in FIG. 1 and below. The present invention encompasses the use of one or more of these markers for identifying and diagnosing SR, SS, and ISS subjects.

Process for the preparation of fosinopril and intermediates thereof

The present invention relates to a process for the preparation of intermediates useful in the synthesis of [1[S(R)],2α,4β]-4-cyclohexyl-1-[[[2-methyl-1-oxypropoxy) propoxy](4-phenylbutyl phosphinyl]acetyl]-L-proline, and the synthesis thereof, in particular as sodium salt (fosinopril sodium).

PROCESS FOR THE PREPARATION OF FOSINOPRIL AND INTERMEDIATES THEREOF

The present invention relates to a process for the preparation of intermediates useful in the synthesis of [1[S(R)],2α,4β]-4-cyclohexyl-1-[[[2-methyl-1-oxypropoxy)propoxy](4-phenylbutyl phosphinyl]acetyl]L-proline, and the synthesis thereof, in particular as sodium salt (fosinopril sodium).

Process for the preparation of fosinopril and intermediates thereof

Process for the preparation of intermediates useful in the synthesis of [1[S(R)],2α,4β]-4-cyclohexyl-1-[[[(2-methyl-1-oxypropoxy) propoxy](4-phenylbutyl) phosphinyl]acetyl]-L-proline, and the synthesis thereof, in particular as sodium salt.